{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:41:02Z","timestamp":1790714462093,"version":"4.1.0"},"reference-count":224,"publisher":"Informa UK Limited","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1517\/13543776.2010.510836","type":"journal-article","created":{"date-parts":[[2010,8,11]],"date-time":"2010-08-11T05:57:34Z","timestamp":1281506254000},"page":"1219-1245","source":"Crossref","is-referenced-by-count":79,"title":["Prolyl hydroxylase domain-containing protein inhibitors as stabilizers of hypoxia-inducible factor: small molecule-based therapeutics for anemia"],"prefix":"10.1517","volume":"20","author":[{"given":"Lin","family":"Yan","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA ; ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent J","family":"Colandrea","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA ; ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J","family":"Hale","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Merck Research Laboratories, P.O. Box 2000, Rahway, NJ 07065, USA ; ;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2010,8,11]]},"reference":[{"key":"e_1_3_2_2_1","unstructured":"Worldwide prevalence of anaemia 1993 \u2013 2005 WHO Global Databaseon Anaemia. Available from: http:\/\/whqlibdoc.who.int\/publications\/2008\/978 9241596657_eng.pdf"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-3046"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a071363"},{"key":"e_1_3_2_5_1","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/bmj.2.5469.1036","article-title":"Plasma erythropoietin in chronic uraemia","volume":"2","author":"Brown R","year":"1965","unstructured":"Brown R. Plasma erythropoietin in chronic uraemia. Br Med J 1965;2:1036-8","journal-title":"Br Med J"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0171-2985(86)80101-2"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.1992.72.2.449"},{"issue":"6005","key":"e_1_3_2_8_1","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/313806a0","article-title":"Isolation and characterization of genomic and cDNA clones of human erythropoietin","volume":"313","author":"Jacobs K","year":"1985","unstructured":"Jacobs K, Shoemaker R, Rurensdorf R, Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985;313(6005):806","journal-title":"Nature"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.22.7580"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198907203210305"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-12-992"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06948.x"},{"key":"e_1_3_2_13_1","unstructured":"FibroGen Inc. Avaialble from: http:\/\/www.fibrogen.com\/anemial_market. [Accessed on 18 April 2010]"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000213166"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.12.12.5447-5454.1992"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2761"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.cellbio.15.1.551"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(20)80571-7"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.3.1230"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.11.1.72"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.9.4273"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4773(97)00674-6"},{"key":"e_1_3_2_23_1","first-page":"205","article-title":"Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha","volume":"7","author":"Gu Y-Z","year":"1998","unstructured":"Gu Y-Z, Moran SM, Hogenesch JB, Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998;7:205-13","journal-title":"Gene Expr"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1852076"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.35.21262"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30117"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073123"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13210"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M808737200"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608382104"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-009-0458-z"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.50.32253"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.14.7987"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.51.32529"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.12.5510"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.20.2.429-440.2000"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2009.08.011"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002740200"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.13.5680"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.9.4304"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.1.5145"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31370"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M304982200"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20061151"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059817"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059796"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.181341498"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1073440"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/20459"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/35017054"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.190332597"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209818"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1073440"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature00767"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M804390200"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1068592"},{"key":"e_1_3_2_57_1","doi-asserted-by":"crossref","first-page":"14004","DOI":"10.1016\/S0021-9258(18)92802-4","article-title":"Bovine liver aspartyl beta-hydroxylase","volume":"266","author":"Wang Q","year":"1991","unstructured":"Wang Q, VanDusen WJ, Petroski CJ, Bovine liver aspartyl beta-hydroxylase. J Biol Chem 1991;266:14004-10","journal-title":"J Biol Chem"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082121399"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082117899"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312254200"},{"key":"e_1_3_2_61_1","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bbrc.2005.08.111","article-title":"Signalling hypoxia by HIF hydroxylases","volume":"338","author":"Schfield CJ","year":"2005","unstructured":"Schfield CJ, Ratcliffe PJ. Signalling hypoxia by HIF hydroxylases. Biochem Biophys Res Commun 2005;338:617-26","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(03)00453-4"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(02)00862-8"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M704988200"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00318"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg392"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M804390200"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M601719200"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2006.01.024"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio863"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601283103"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2009.06.002"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161209789649457"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986707781058850"},{"key":"e_1_3_2_75_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.neulet.2004.03.073","article-title":"Activation of HIF-1alpha mRNA by hypoxia and iron chelator in isolated rat carotid body","volume":"363","author":"Roy A","year":"2004","unstructured":"Roy A, Volgin DV, Baby SM, Activation of HIF-1alpha mRNA by hypoxia and iron chelator in isolated rat carotid body. Neurosci Lett 2004;363:229-32","journal-title":"Neurosci Lett"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.02-0586fje"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-3399fje"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2849206"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M403057200"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/0076-6879(82)82067-3"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1177\/1087057109333976"},{"key":"e_1_3_2_82_1","unstructured":"FibroGen Inc. HIF prolyl hydroxylase activity assay. WO2005118836; 2007"},{"key":"e_1_3_2_83_1","doi-asserted-by":"crossref","first-page":"55051","DOI":"10.1074\/jbc.M410287200","article-title":"Many amino acid substitutions in a hypoxia-inducible transcription factor (HIF)-1alpha-like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases","volume":"279","author":"Li D","year":"2004","unstructured":"Li D, Hirsila M, Koivunen P, Many amino acid substitutions in a hypoxia-inducible transcription factor (HIF)-1alpha-like peptide cause only minor changes in its hydroxylation by the HIF prolyl 4-hydroxylases. J Biol Chem 2004;279:55051-9","journal-title":"J Biol Chem"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2008.09.052"},{"key":"e_1_3_2_85_1","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1016\/j.bmcl.2008.06.031","article-title":"Discovery of novel hydroxyl-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation","volume":"18","author":"Tegley CM","year":"2008","unstructured":"Tegley CM, Viswanadhan VN, Biswas K, Discovery of novel hydroxyl-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation. Bioorg Med Chem Lett 2008;18:3925-8","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2008.08.012"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2004.03.066"},{"key":"e_1_3_2_88_1","unstructured":"FibroGen Inc. Stabilization of hypoxia inducible factor (HIF) alpha. WO2003049686; 2003"},{"key":"e_1_3_2_89_1","unstructured":"FibroGen Inc. Methods of increasing endogenous EPO. WO2003053997; 2003"},{"key":"e_1_3_2_90_1","unstructured":"FibroGen Inc. Treatment method for anemia. US20060276477; 2006"},{"key":"e_1_3_2_91_1","unstructured":"FibroGen Inc. Compounds and methods for treatment of chemotherapy-induced anemia. US20070292433; 2007"},{"key":"e_1_3_2_92_1","unstructured":"FibroGen Inc. HIF hydroxylase inhibitors for treatment of cancer-related anemia. US20070293575; 2007"},{"key":"e_1_3_2_93_1","unstructured":"FibroGen Inc. Use of HIF alpha stabilizers for enhancing erythropoiesis. WO2004108121; 2004"},{"key":"e_1_3_2_94_1","unstructured":"FibroGen Inc. Cytoprotection through the use of HIF hydroxylase inhibitors. US20060251638; 2006"},{"key":"e_1_3_2_95_1","unstructured":"FibroGen Inc. Fat regulation. WO2004052285; 2004"},{"key":"e_1_3_2_96_1","unstructured":"FibroGen Inc. Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers. WO2005011696; 2005"},{"key":"e_1_3_2_97_1","unstructured":"FibroGen Inc. Tissue remodeling and vascularization. WO2005034929; 2005"},{"key":"e_1_3_2_98_1","unstructured":"FibroGen Inc. Treatment of diabetes. WO2004052284; 2004"},{"key":"e_1_3_2_99_1","unstructured":"FibroGen Inc. Methods of identifying therapeutic targets for the treatment of vulvovaginal atrophy. WO2006099610; 2006"},{"key":"e_1_3_2_100_1","unstructured":"FibroGen Inc. Compounds and methods for treatment of stroke. WO2007097929; 2007"},{"key":"e_1_3_2_101_1","unstructured":"FibroGen Inc. Methods for increasing endothelial progenitor cells. WO2009075824; 2009"},{"key":"e_1_3_2_102_1","unstructured":"FibroGen Inc. Methods for increasing white blood cells. WO2009075826; 2009"},{"key":"e_1_3_2_103_1","unstructured":"FibroGen Inc. Compounds and methods for treatment of cancer. WO2006138511; 2006"},{"key":"e_1_3_2_104_1","unstructured":"FibroGen Inc. Methods for reducing blood pressure. WO2009058403; 2009"},{"key":"e_1_3_2_105_1","unstructured":"FibroGen Inc. Phenanthroline derivatives. WO9921860; 1999"},{"key":"e_1_3_2_106_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.192342099"},{"key":"e_1_3_2_107_1","unstructured":"FibroGen Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin. WO2004108681; 2004"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jasms.2007.11.003"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.08.017"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm900285r"},{"key":"e_1_3_2_111_1","unstructured":"FibroGen Inc. Novel thienopyridine compounds and methods of use thereof. WO2006094292; 2006"},{"key":"e_1_3_2_112_1","unstructured":"FibroGen Inc. Cyanoisoquinoline compounds and methods of use thereof. WO2007090068; 2007"},{"key":"e_1_3_2_113_1","unstructured":"FibroGen Inc. Preparation of pyrrolopyridines and thiazolopyridines particularly N-[(4-hydroxy-1H-pyrrolo[2 3-c]pyridin-5-yl)carbonyl]glycine and N-[(7-hydroxythiazolo[4 5-c]pyridine-6-yl)carbonyl]glycine derivatives as hypoxia inducible factor hydroxylase modulators. WO2007115315; 2007"},{"key":"e_1_3_2_114_1","unstructured":"FibroGen Inc. Isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions. WO2009073669; 2009"},{"key":"e_1_3_2_115_1","unstructured":"FibroGen Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity. WO2009089547; 2009"},{"key":"e_1_3_2_116_1","unstructured":"FibroGen Inc. Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors. WO2009100250; 2009"},{"key":"e_1_3_2_117_1","unstructured":"FibroGen Inc. Thiochromene derivatives as HIF hydroxylase inhibitors. WO2010056767; 2010"},{"key":"e_1_3_2_118_1","unstructured":"FibroGen Inc. Pyrrolo[1 2-b]pyridazine derivatives and their use as HIF modulators. WO2010022240; 2010"},{"key":"e_1_3_2_119_1","unstructured":"GlaxoSmithKline. Anti-infectives. WO2004052313; 2004"},{"key":"e_1_3_2_120_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase antagonists. WO2007038571; 2007"},{"key":"e_1_3_2_121_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2007103905; 2007"},{"key":"e_1_3_2_122_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2007136990; 2007"},{"key":"e_1_3_2_123_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009039323; 2009"},{"key":"e_1_3_2_124_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009039321; 2009"},{"key":"e_1_3_2_125_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009039322; 2009"},{"key":"e_1_3_2_126_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010022307; 2010"},{"key":"e_1_3_2_127_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009070644; 2009"},{"key":"e_1_3_2_128_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009073497; 2009"},{"key":"e_1_3_2_129_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009134850; 2009"},{"key":"e_1_3_2_130_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009134847; 2009"},{"key":"e_1_3_2_131_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2007150011; 2007"},{"key":"e_1_3_2_132_1","unstructured":"GlaxoSmithKline. N-Substituted glycine derivatives: prolyl hydroxylase inhibitors. US20080171756; 2008"},{"key":"e_1_3_2_133_1","unstructured":"GlaxoSmithKline. N-Substituted glycine derivatives: hydroxylase inhibitors. WO2008089052; 2008"},{"key":"e_1_3_2_134_1","unstructured":"GlaxoSmithKline. N-Glycinyl pyridinedicarboxamide derivatives as HIF prolyl hydroxylase inhibitors and their preparation pharmaceutical compositions and use in the treatment of anemia. WO2009158315; 2009"},{"key":"e_1_3_2_135_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010025087; 2010"},{"key":"e_1_3_2_136_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009049112; 2009"},{"key":"e_1_3_2_137_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2009086044; 2009"},{"key":"e_1_3_2_138_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010022308; 2010"},{"key":"e_1_3_2_139_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010059549; 2010"},{"key":"e_1_3_2_140_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010059552; 2010"},{"key":"e_1_3_2_141_1","unstructured":"GlaxoSmithKline. Prolyl hydroxylase inhibitors. WO2010059555; 2010"},{"key":"e_1_3_2_142_1","unstructured":"Amgen. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity and compositions and uses thereof. WO2007070359; 2007"},{"key":"e_1_3_2_143_1","unstructured":"Amgen. Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity compositions and uses thereof. WO2008076425; 2008"},{"key":"e_1_3_2_144_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm900285r"},{"key":"e_1_3_2_145_1","unstructured":"Amgen. Diazaquinolones that inhibit prolyl hydroxylase activity. WO2008137084; 2008"},{"key":"e_1_3_2_146_1","unstructured":"Amgen. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity compositions and uses thereof. WO2008076427; 2008"},{"key":"e_1_3_2_147_1","unstructured":"Amgen. Indanone derivatives that inhibit prolyl hydroxylase. WO2008130508; 2008"},{"key":"e_1_3_2_148_1","unstructured":"Amgen. Quinolones and azaquinolones that inhibit prolyl hydroxylase. WO2008130600; 2008"},{"key":"e_1_3_2_149_1","unstructured":"Amgen. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity. WO2008137060; 2008"},{"key":"e_1_3_2_150_1","unstructured":"Bayer. 4-(Pyridin-3-yl)-2-(pyridine-2-yl)-1 2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-prolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases. WO2006114213; 2006"},{"key":"e_1_3_2_151_1","unstructured":"Bayer. Substituted dipyridyl-dihydropyrazolones and use thereof. WO2008067874; 2008"},{"key":"e_1_3_2_152_1","unstructured":"Bayer. Substituted heterocyclic compounds and their use. DE102007044032; 2007"},{"key":"e_1_3_2_153_1","unstructured":"Bayer. Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors. WO2008049538; 2008"},{"key":"e_1_3_2_154_1","unstructured":"Bayer. Substituted dihydropyrazolthiones and their use. DE102007048447; 2007"},{"key":"e_1_3_2_155_1","unstructured":"Bayer. Substituted dihydrotriazolones and their use. DE102007049157; 2007"},{"key":"e_1_3_2_156_1","unstructured":"Bayer. Substituted dihydropyrazolones for treating cardiovascular and haematological diseases. WO2008067871; 2008"},{"key":"e_1_3_2_157_1","unstructured":"Bayer. Substituted dihydropyrazolones and their use. US20090269420; 2009"},{"key":"e_1_3_2_158_1","unstructured":"Merck. Novel 1 8-naphthyridine compounds. WO2008130527; 2008"},{"key":"e_1_3_2_159_1","unstructured":"Merck. Tetrahydrofuropyridines. WO2009108496; 2009"},{"key":"e_1_3_2_160_1","unstructured":"Merck. Tetrahydrothienopyridines. WO2009108497; 2009"},{"key":"e_1_3_2_161_1","unstructured":"Merck. Tetrahydro-1H-pyrrolo fused pyridones. WO2009108499; 2009"},{"key":"e_1_3_2_162_1","unstructured":"Merck. Spiroindalones. WO2008144266; 2008"},{"key":"e_1_3_2_163_1","unstructured":"Merck. Spiroazaindoles. WO2009137291; 2009"},{"key":"e_1_3_2_164_1","unstructured":"Merck. Substituted 4-hydroxypyrimidine-5-carboxamides. WO2009117269; 2009"},{"key":"e_1_3_2_165_1","unstructured":"Janssen. Benzoimidazoles as prolyl hydroxylase inhibitors. WO2009134750; 2009"},{"key":"e_1_3_2_166_1","unstructured":"Benzoimidazoles glycinamides as prolyl hydroxylase inhibitors. WO2009134754; 2009"},{"key":"e_1_3_2_167_1","unstructured":"Procter & Gamble. Three dimensional coordinates of hypoxia inducible factor 1 alpha (HIF-1alpha)-prolyl hydroxylase (EGLN1) and uses thereof. US20080124740; 2008"},{"key":"e_1_3_2_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.08.040"},{"key":"e_1_3_2_169_1","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1016\/j.bmcl.2006.08.026","article-title":"Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydrolase inhibitors","volume":"16","author":"Warshakoon NC","year":"2006","unstructured":"Warshakoon NC, Wu S, Boyer A, Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydrolase inhibitors. Bioorg Med Chem Lett 2006;16:5616-20","journal-title":"Bioorg Med Chem Lett"},{"key":"e_1_3_2_170_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2006.08.089"},{"key":"e_1_3_2_171_1","unstructured":"Procter & Gamble. Prolyl hydroxylase inhibitors and methods of use. US20070299086; 2007"},{"key":"e_1_3_2_172_1","unstructured":"CrystalGenomics. Pyridine derivatives and methods of use thereof. WO2009037570; 2009"},{"key":"e_1_3_2_173_1","unstructured":"CrystalGenomics. Phenol derivatives and methods of use thereof. WO2010018458; 2010"},{"key":"e_1_3_2_174_1","unstructured":"Kowa. Prophylactic and\/or therapeutic agent for anemia comprising 2-phenylquinoline-4-carboxylic acid derivative as active ingredient. WO2009016812; 2009"},{"key":"e_1_3_2_175_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2009.2711"},{"key":"e_1_3_2_176_1","article-title":"Upregulation of endogenous erythropoietin (EPO) in healthy subjects by inhibition of hypoxia inducible factor (HIF) prolyl hydroxylase. American Society of Hematology 2004 Annual Meeting","volume":"104","author":"Urquilla P","year":"2004","unstructured":"Urquilla P, Fong A, Oksanen S, Upregulation of endogenous erythropoietin (EPO) in healthy subjects by inhibition of hypoxia inducible factor (HIF) prolyl hydroxylase. American Society of Hematology 2004 Annual Meeting. Blood 2004;104:abstract 174","journal-title":"Blood"},{"key":"e_1_3_2_177_1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2174\/156652409788167113","article-title":"Hypoxic tumor microenvironment and cancer cell differentiation","volume":"9","author":"Kim Y","year":"2009","unstructured":"Kim Y, Lin Q, Glazer PM, Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 2009;9:425-34","journal-title":"Curr Mol Med"},{"key":"e_1_3_2_178_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.22214"},{"key":"e_1_3_2_179_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1187"},{"key":"e_1_3_2_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4914(02)02317-1"},{"key":"e_1_3_2_181_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-677"},{"key":"e_1_3_2_182_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14567-9"},{"key":"e_1_3_2_183_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.150"},{"key":"e_1_3_2_184_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.061"},{"key":"e_1_3_2_185_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-437X(00)00152-0"},{"key":"e_1_3_2_186_1","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1056\/NEJMoa0806277","article-title":"PHD2 mutation and congenital erythrocytosis with paragandlioma","volume":"259","author":"Ladroue C","year":"2008","unstructured":"Ladroue C, Carcenac R, Leporrier M, PHD2 mutation and congenital erythrocytosis with paragandlioma. N Engl J Med 2008;259:2685-92","journal-title":"N Engl J Med"},{"key":"e_1_3_2_187_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/3.5.461"},{"key":"e_1_3_2_188_1","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2307\/3577265","article-title":"Altitude, radiation, and mortality from cancer and heart disease","volume":"112","author":"Weinberg CR","year":"1987","unstructured":"Weinberg CR, Brown KG, Hoel DG. Altitude, radiation, and mortality from cancer and heart disease. Radiat Res 1987;112:381-90","journal-title":"Radiat Res"},{"key":"e_1_3_2_189_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5449.2511"},{"key":"e_1_3_2_190_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.914801"},{"key":"e_1_3_2_191_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.01.020"},{"key":"e_1_3_2_192_1","doi-asserted-by":"publisher","DOI":"10.1086\/377108"},{"key":"e_1_3_2_193_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1019"},{"key":"e_1_3_2_194_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2535"},{"key":"e_1_3_2_195_1","doi-asserted-by":"publisher","DOI":"10.1089\/scd.2009.0402"},{"key":"e_1_3_2_196_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0508423103"},{"key":"e_1_3_2_197_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-084434"},{"key":"e_1_3_2_198_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2007.07.017"},{"key":"e_1_3_2_199_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.12.3610.3610"},{"key":"e_1_3_2_200_1","unstructured":"Novartis Pharmaceuticals Corporation. Available from: http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/exjade.pdf [Accessed 12 April 2010]"},{"key":"e_1_3_2_201_1","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/187152009788451806","article-title":"Role of oxygen in cancer: looking beyond hypoxia","volume":"9","author":"Lopez-Lazaro M","year":"2009","unstructured":"Lopez-Lazaro M. Role of oxygen in cancer: looking beyond hypoxia. Anticancer Agents Med Chem 2009;9:517-25","journal-title":"Anticancer Agents Med Chem"},{"key":"e_1_3_2_202_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp038177"},{"key":"e_1_3_2_203_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2148"},{"key":"e_1_3_2_204_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp0912328"},{"key":"e_1_3_2_205_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2008.04.003"},{"key":"e_1_3_2_206_1","first-page":"546A","article-title":"Up-regulation of endogenous EPO in healthy subjects by inhibition of HIF-PH","volume":"15","author":"Urquilla P","year":"2004","unstructured":"Urquilla P. Up-regulation of endogenous EPO in healthy subjects by inhibition of HIF-PH. J Am Soc Nephrol 2004;15:546A","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_2_207_1","first-page":"758A","article-title":"FG-2216 increases hemoglobin concentration in anemic patients with chronic kidney disease","volume":"16","author":"Gunzler V","year":"2005","unstructured":"Gunzler V, Muthukrishnan E, Neumayer HH, FG-2216 increases hemoglobin concentration in anemic patients with chronic kidney disease. J Am Soc Nephrol 2005;16:758A","journal-title":"J Am Soc Nephrol"},{"key":"e_1_3_2_208_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2009.01.018"},{"key":"e_1_3_2_209_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107123450206"},{"key":"e_1_3_2_210_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00052403"},{"key":"e_1_3_2_211_1","first-page":"744","article-title":"Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia","volume":"91","author":"Bushuev VI","year":"2006","unstructured":"Bushuev VI, Miasnikova GY, Sergueeva AI, Endothelin-1, vascular endothelial growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. Haematologica 2006;91:744-9","journal-title":"Haematologica"},{"key":"e_1_3_2_212_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030290"},{"key":"e_1_3_2_213_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfi098"},{"key":"e_1_3_2_214_1","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000104443","article-title":"Pulmonary hypertension and erythropoietin","volume":"30","author":"Beumi M","year":"2007","unstructured":"Beumi M, Senatore M, Gallo GC, Pulmonary hypertension and erythropoietin. Kidney Blood Press Res 2007;30:248-52","journal-title":"Kidney Blood Press Res"},{"key":"e_1_3_2_215_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.6.803"},{"key":"e_1_3_2_216_1","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1152\/japplphysiol.00965.2001","article-title":"Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1","volume":"92","author":"Balanos GM","year":"2002","unstructured":"Balanos GM, Dorrington KL, Robbins PA. Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol 2002;92:2501-7","journal-title":"J Appl Physiol"},{"key":"e_1_3_2_217_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2008.160960"},{"key":"e_1_3_2_218_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5912"},{"key":"e_1_3_2_219_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI15496"},{"key":"e_1_3_2_220_1","first-page":"3879","article-title":"Von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythrocytosis","volume":"117","author":"Hickey MM","year":"2007","unstructured":"Hickey MM, Lam JC, Bezman NA, Von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythrocytosis. J Clin Invest 2007;117:3879-89","journal-title":"J Clin Invest"},{"key":"e_1_3_2_221_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36362"},{"key":"e_1_3_2_222_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi801624f"},{"key":"e_1_3_2_223_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0602235103"},{"key":"e_1_3_2_224_1","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.2174\/138161209789649411","article-title":"HIF prolyl-4-hydroxylase interacting proteins: consequences for drug targeting","volume":"15","author":"Wenger RH","year":"2009","unstructured":"Wenger RH, Camenisch G, Stiehl DP, HIF prolyl-4-hydroxylase interacting proteins: consequences for drug targeting. Curr Pharm Des 2009;15:3886-94","journal-title":"Curr Pharm Des"},{"key":"e_1_3_2_225_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio0308-152"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/13543776.2010.510836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T23:36:26Z","timestamp":1770939386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1517\/13543776.2010.510836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,11]]},"references-count":224,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1517\/13543776.2010.510836"],"URL":"https:\/\/doi.org\/10.1517\/13543776.2010.510836","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,11]]}}}